Third-party tested
Ipamorelin
A selective pentapeptide ghrelin-receptor (GHSR-1a) agonist, studied for growth hormone release in research models.
Availability: 5 in stock
Ipamorelin, by the numbers.
Structural and laboratory facts that define this compound. For laboratory research use only.
Synthetic pentapeptide
g/mol · C38H49N9O5
GHSR-1a (ghrelin receptor)
Novo Nordisk research
The Ipamorelin molecule
A schematic atomic representation shown next to the compound's molecular data. The figure is illustrative, not a measured conformation.
How it is studied.
The first truly selective GH secretagogue — GH release without cortisol, ACTH, or prolactin elevation
Ipamorelin selectively binds Growth Hormone Secretagogue Receptor 1a (GHSR-1a) on anterior pituitary somatotrophs, triggering GH release in a dose-dependent manner. It acts via the same receptor as ghrelin but with greater selectivity and without the appetite-stimulating off-target effects.
- Selective GHSR-1a (ghrelin receptor) agonism
- Dose-dependent GH release (ED50: 80 nmol/kg)
- No desensitization with repeated administration
Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate ACTH, cortisol, or prolactin at doses that produce substantial GH release. This was demonstrated in dose-escalation studies and marks ipamorelin as the first pentapeptide GH secretagogue with this selectivity profile.
- No ACTH or cortisol elevation (unlike GHRP-6)
- No significant prolactin elevation
- Clean pituitary selectivity
Ipamorelin stimulates GH release in discrete, pulsatile bursts similar to endogenous GH secretion physiology. This pulsatile pattern is considered more physiologically appropriate than continuous GH elevation, and is preserved across multiple administration cycles.
- Preserves pulsatile GH secretion pattern
- Peak GH at approximately 40 minutes post-dose
- Additive effect when combined with GHRH analogs
Research pathway map
The primary pathways Ipamorelin is investigated against in laboratory models.
Compound details.
Storage & handling
Supplied as a lyophilized powder. Store the sealed vial refrigerated at 2–8°C, protected from light and moisture; −20°C for long-term storage. Keep reconstituted material refrigerated.
Eur J Endocrinol · 1998Ipamorelin, the first selective growth hormone secretagogue
Original pharmacological characterization.
Raun K et al., 1998 · PubMed ↗Growth Horm IGF Res · 1999Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
Rodent model study.
Johansen PB et al., 1999 · PubMed ↗Pharm Res · 1999Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Pharmacokinetic modeling study.
Gobburu JV et al., 1999 · PubMed ↗
